化合物 Pyrintegrin T16695
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
25 mg | 1228445-38-2 | ¥3,990.00 | 询底价 |
10 mg | 1228445-38-2 | ¥2,180.00 | 询底价 |
100 mg | 1228445-38-2 | ¥7,930.00 | 询底价 |
5 mg | 1228445-38-2 | ¥1,470.00 | 询底价 |
1 mg | 1228445-38-2 | ¥625.00 | 询底价 |
2 mg | 1228445-38-2 | ¥912.00 | 询底价 |
50 mg | 1228445-38-2 | ¥5,680.00 | 询底价 |
1 mL | 1228445-38-2 | ¥1,620.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Pyrintegrin
描述: Pyrintegrin 是一种 β1 整合素激动剂,也是 2,4-二取代的嘧啶,可促进胚胎干细胞存活。它可用作足细胞保护剂,能增强细胞-细胞外基质 (ECM) 粘附介导的整联蛋白信号传导,具有强大的成脂作用。
体外活性: Pyrintegrin decreases Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation. Pyrintegrin treatment prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells. Pyrintegrin stimulates human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol, and total triglycerides. Pyrintegrin (0-10 μM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC50 of 1.14 μM) [1][2].
体内活性: Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. Pyrintegrin decreases peak proteinuria caused by puromycin aminonucleoside-induced nephropathy. Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation. Pyrintegrin (10 mg/kg; intraperitoneal injection; once; C57BL/6J mice) treatment protects mice from LPS-induced podocyte foot process effacement and proteinuria. LPS administration decreases the levels of active β1 integrin in the podocytes, which is prevented by cotreatment with Pyrintegrin [1][2].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 250 mg/mL (553.66 mM)
关键字: nephropathy | C/EBPα | embryonic | stem | inhibit | β1-integrin | PPARγ | Integrin | Pyrintegrin | Adipogenic | cells | Inhibitor | podocyte-protective | ECM | proteinuria
相关产品: Cyclo(-RGDfK) TFA | P11 acetate | BMS-688521 | Firategrast | Roxifiban acetate | Bexotegrast | αvβ6 integrin inhibitor 2 | Bersanlimab | Bimosiamose | ILK-IN-2
相关库: Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | NO PAINS Compound Library | Bioactive Compound Library
化合物 Pyrintegrin T16695信息由TargetMol中国为您提供,如您想了解更多关于化合物 Pyrintegrin T16695报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途